pull down to refresh

96 sats \ 4 replies \ @freetx 21 Feb \ parent \ on: The Ozempic Shortage Is Over HealthAndFitness
In July 2024, a study published in the journal JAMA Ophthalmology found a potential link between semaglutide — the active ingredient in Wegovy and Ozempic — and a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION).
https://www.medicalnewstoday.com/articles/review-3-potentially-blinding-eye-conditions-glp-1-drugs-ozempic-mounjaro#GLP-1-meds-and-eye-conditions
write
preview
30 sats \ 1 reply \ @gmd 21 Feb
yeah i saw that study floating around twitter a few months ago (but admittedly did not read).
Would be curious to see if that association holds with the newer meds. My gut (lowest tier of evidence) from seeing patients who would never give up these and talking to docs who prescribe thinks there is 4-5x or greater benefit over any risks from cardiovascular risks from eliminating being a fatty and controlling diabetes.
reply
66 sats \ 0 replies \ @oliverweiss 21 Feb
gut (lowest tier of evidence) This is great, will start using it! 🙂
reply
66 sats \ 1 reply \ @oliverweiss 21 Feb
Interesting. The question is if the blindness was really caused by the drug, I mean it is known that obesity may lead to diabetes and diabetes to blindness. It could just be that the drugs didn’t really work, the patients developed diabetes…
I can also imagine that some people at Novo Nordisk got nervous by this news 😬
reply
40 sats \ 0 replies \ @gmd 22h
Even if there is a higher association of NAION caused by these drugs, I would want to know how that compares to the greater risk of diabetic retinopathy. I have seen NAION less than a handful of times, whereas I see diabetic retinopathy and other complications of diabetes every day.
Too lazy to look up actual numbers with cited sources but O1 vibe check says:
NAION: Often cited around 2–10 per 100,000 persons per year (for individuals over 50). Diabetic Retinopathy : Multiple large-scale studies (e.g., NHANES in the United States) have reported that anywhere from 20% to 40% (or more) of people with diabetes show some level of retinopathy Putting It All Together:
  • NAION in diabetics: Elevated risk vs. non-diabetics, but still a relatively uncommon event.
  • Diabetic Retinopathy (and its advanced stages) is very common in long-standing diabetes—often cited as the leading cause of new cases of blindness among working-age adults in many countries.
reply